Development of UM-1098: a novel synthetic TH17 inducing adjuvant and delivery system

Active Definitive Contract Awarded Last action

Contract number
75N93023C00047
Awardee
Awarding agency
Obligated
$12,859,404

Award facts

Opportunity
  • 75N93022R00009 Solicitation number
Contract value 100% obligated
$12,859,404.00 Current and potential, with all options
Completion date 62% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 24 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Missoula, MT 59812, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Exercise an Option P00005 · EO14398; "development of UM-1098: a novel synthetic TH17 inducing adjuvant and delivery system" $3,293,198
Change Order P00004 · EOI::EO: radical transparency about wasteful spending: EOI bilateral modification to descope for FY2025 cost savings: "development of UM-1098: a novel synthetic… $1,641,451
Other Administrative Action P00003 $0
Change Order P00002 $3,504,851
Exercise an Option P00001 $2,000,000
Original award $2,419,904

About this award

The National Institute of Allergy and Infectious Diseases awarded a definitive contract to University of Montana for development of UM-1098, a novel synthetic TH17-inducing adjuvant and delivery system, on September 30, 2023, with a ceiling value of $12.859 million and ultimate completion date of September 29, 2028.

Place of performance is Missoula, Montana. The contract is firm fixed price with no set-aside designation.

The originating solicitation calls for development of a vaccine adjuvant candidate, including scale-up and process development on a 50-gram scale, analytical assay development for active pharmaceutical ingredient and final product release, product release specifications and manufacturing batch record preparation, pre-cGMP formulation lot preparation sufficient for non-clinical IND-enabling studies, and oversight of non-GLP toxicology and pharmacokinetic/ADME studies. Subcontractors include Montana State University (adjuvant production and analytical support), Inimmune Corp (scale-up, process development, and formulation activities), The University of Chicago (in vitro, ex vivo, and in vivo evaluation of optimized formulations in mice and non-human primates), Icahn School of Medicine at Mount Sinai (H5N1 and H5N2 subunit vaccine development), and West Virginia University Research Corporation (SARS-CoV-2 vaccine evaluation).

Service Contract Inventory reporting shows FY2025 invoicing of $2.4 million across 1.6 FTEs and 3,305 contractor hours, with a derived government-paid hourly rate of $738.20/hr. Subcontractors accounted for 54% of contractor hours in FY2025. FY2024 reported $1.2 million invoiced across 92 contractor hours at a blended rate of $13,481.17/hr reflecting minimal labor footprint early in performance.

Subawards

Subcontractor Amount Awarded
Montana State University DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM To develop a novel vaccine against Lyme disease, we will leverage the ΦBB-1… $132,500
Inimmune Corp DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM Continuation of the work performed under PG25-61369-03 and PG25-61419-02.… $233,377
The University Of Chicago DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM a. Product development activities Specifically, the Subcontractor shall: 1.… $549,775
Inimmune Corp DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM The Inimmune team will be responsible for 1) scale-up and process… $80,651
Icahn School Of Medicine At Mount Sinai DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM Develop and advance a durable cross-protective adjuvanted H5N1 and H5N2… $575,022
West Virginia University Research Corporation DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM Evaluate the breadth, durability and safety of next-generation adjuvanted… $415,626
Inimmune Corp DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM The vaccine research and development teams at University of Montana… $649,639
Inimmune Corp DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM Inimmune Corporation, Kendal Ryter, Ph.D. – The Inimmune team, under… $63,890
The University Of Chicago DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM Technical Requirements Independently, and not as an agent of the… $566,369

Quick answers

Who was awarded contract 75N93023C00047?

75N93023C00047 was awarded to University Of Montana by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2023.

How much is contract 75N93023C00047 worth?

The government has obligated $12,859,404 on 75N93023C00047.

Was contract 75N93023C00047 competed?

The extent of competition for 75N93023C00047 was full and open competition. The government received 24 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award